Skip to main content

Spectrum of EGFR mutation and its relation with high-risk predictors in thyroid cancer in Kashmiri population: 2 years prospective study at a tertiary care hospital



EGFR mutation has not been extensively studied in thyroid cancer. This study was conducted to study spectrum of EGFR mutation in thyroid cancer in Kashmiri population for possible therapeutic purpose.


It was 2 years prospective cross-sectional study conducted at a tertiary care center in which histologically confirmed, untreated thyroid cancers were included. These specimens were subjected to EGFR mutation analysis by AS-PCR method.


There were a total 60 patients with preponderance of females [44(73%) vs 16(27%)]. Most were in the age group of less than 45 years (75%). Most of these patients were non-smokers [50(83.3%) vs 10 (17.3%)]. Papillary thyroid carcinoma (PTC) was the commonest type 48(80%), rest was follicular type (FTC) 12(20%). Well-differentiated carcinoma (WDC) was common than poorly differentiated (PDC) [41(68.4%) vs 19 (31.6%)]. Lymph node metastasis and vascular invasion were present in 32 (53.4%) and 17 (28.4%) respectively. Thirty-two (53.3%) patients were having 15 bp deletion in exon 19 of EGFR. These deletions were common in PTC than FTC, 29(60.5%) vs 3(25%) which was statistically significant (p = 0.04, CI = 0.2). The total mutational rate of T790M in EGFR tyrosine kinase domain (exon 20) was found to be only 8.4% (5 of 60). Only 4 (8.3%) of these mutations were detected in PTC and rest in FTC (1 of 12). Twenty-six (43.3%) of exon 21 were positive for L858R mutation in EGFR tyrosine kinase domain. Married persons and PDC were significant predictors of L858R mutation in EGFR tyrosine kinase domain in thyroid cancer as this was statistically significant in them with p = 0.04, 0.03 respectively.


In our population, PTC is common in females with half of population harboring EGFR mutation and it is statistically significant in poorly differentiated carcinoma and in married individuals.

It implies that EGFR may be used in thyroid cancer as a possible therapeutic agent in our set of population.


Thyroid cancer is one of the most common endocrine tumors worldwide [1, 2]. Papillary and follicular constitute about 90% among all types of thyroid malignancies [3, 4]. Prevalence of thyroid cancer is about 1–5% and 2% in females and males respectively. With the advent of new diagnostic modalities, the incidence of thyroid cancer is increasing [5]. There are various clinicopathologic criteria on which prognosis of thyroid cancer depends: age, gender, histologic subtype, tumor size, extrathyroidal extension (ETE), and the presence of lymph node (LNM) or distant metastases [6]. After a 20-year period of a relatively flat mortality rate, there has been a recent increase in thyroid carcinoma related mortality especially in men [7]. This has led to a greater interest in understanding tumor-specific markers in thyroid cancer to identify specific patients who can have adverse outcome.

Epidermal growth factor receptor (EGFR) refers to a mutation to the portion of DNA in a cancer cell (particularly lung cancer which carries the stimulus for making EGFR protein), allowing cancer cells to grow and spread. EGFR is one of the novel tumor markers, which has been studied extensively in lung cancer. EGFR is a transmembrane tyrosine kinase (TK) receptor. It is expressed in a variety of neoplastic and non-neoplastic tissues. Both mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways are important for thyroid tumor progression. EGFR plays an important role in activating these pathways [8]. Papillary thyroid cancers (PTCs) expressing EGFR was demonstrated by Landriscina et al. and it is overexpressed by PTCs during dedifferentiation and anaplastic transformation [9]. EGFR overexpression is described in various thyroid malignancies: anaplastic thyroid cancers (ATCs), [10] follicular thyroid cancers (FTCs) [11, 12] and even medullary thyroid cancers (MTCs). However, some studies describe absence of somatic mutations in thyroid cancers [13, 14].

EGFR mutation is best characterized in lung adenocarcinoma, a specific activating mutation that affect the EGFR TK domain. The commonest mutations are deletions in exon 19 (del 2235-2249/2236-2250; del E746-A750), followed by a point mutation in exon 21 (T>G 2573) which results in substitution of leucine by arginine at codon 858 (L858R) [15]. Although similar somatic mutations are described in thyroid cancers [16] they are not well characterized [17]. However, there are some studies that fail to identify them [14, 18].

This study was carried to find out type of specific mutation that is incriminated in progression of thyroid cancer and their relationship with clinical parameters. Probably, it is first such kind of study in North India.


A total of 60 (n = 60) histologically confirmed, previously untreated thyroid cancer patients attending Department of General and Minimal Access Surgery at a tertiary care center were included in this study. Tumor tissue along with corresponding normal tissue was available for all 60 patients. This was prospective cross-sectional study spanned for 2 years from January 2017 to January 2019. A written pre-informed consent was obtained from all cases. Demographic and clinicopathological characteristics of each patient were recorded in a questionnaire. In preoperative assessment of thyroid swelling, all those patients who had significant neck lymph node on Ultra sonography, were subjected to FNAC if it showed metastasis, neck dissection was carried out and on histopathology staging was done. Various clinical features were taken to find out relationship between thyroid cancer and EGFR mutation. Age is one of the prognostic factors in thyroid cancer, so we divided our patients into two groups: one with age > 45 years and other with age < 45 years and use of oral contraceptives is one of the risk factors associated with thyroid cancer. Somatic mutation screening was done on surgically resected and histopathological confirmed tumor and the corresponding normal tissues of thyroid cancer patients. EGFR mutational analysis was seen on exon 19, 20, 21. This study was approved by the Institutional Ethical committee.

Sample collection/storage

The surgically resected tissue samples either by total thyroidectomy/hemi-thyroidectomy or lobectomy, were collected directly into sterile vials containing chilled PBS (Phosphate buffered saline) (pH = 7.2) and frozen at – 80 °C for molecular investigations. Adjacent normal tissues were resected from outside the margins of resection. Histopathologically, confirmed thyroid cancer tissues and corresponding normal tissues were used for mutational analysis of EGFR gene.

Method used for extraction of DNA

DNA was extracted from the tissues by phenol-chloroform method and by Qiagen DNA extraction kit while salting out method was used for the extraction of DNA from blood samples.

The concentration of the DNA obtained was measured in a spectrophotometer at 260 nm wavelength by using the formula:

$$\mathrm{DNA}\ \upmu \mathrm{g}/\mathrm{ml}={A}_{260}\times 50\times \mathrm{dilution}\ \mathrm{factor}$$

The purity of DNA was checked by using A260/A280 ratio. The quality of the DNA obtained from the tissue specimens and blood samples was analyzed on 1% agarose gel. The high-molecular-weight DNA was used for further molecular investigation.

Allele-specific PCR (AS-PCR)

Given the high frequency of EGFR mutations and the possible implication of this receptor in the development of thyroid cancer, it was important to develop a simple, fast, and reliable method to identify these mutations in greater detail as a potential tool for the diagnosis and follow-up of these patients. The mutations in exon 19, 20, and 21 of EGFR gene account for more than 95% of total mutations in the gene. These mutations therefore represent an excellent target for assays, such as AS-PCR that depends on the specific detection of point mutations. The general principle underlying the AS-PCR technique is to design a mutation-specific primer that produces the preferential amplification of a specific mutant allele. The schematic representation of this AS-PCR is shown in Fig. 1.

  1. 1)

    Four primers were used in a single tube to setup an ARMS PCR for exon 19 (15 bp deletion; codons 746–750) of EGFR gene (Fig. 2)

  2. 2)

    Four primers were used in a two-tube reaction for setting up of AS-PCR for the detection of mutation in exon 20 (T790M) (Fig. 3)

  3. 3)

    Two allele specific primers and a single common primer were used in two tubes to determine the exon 21 mutations (L858R) in EGFR gene of thyroid cancer patients (Fig. 4, Table 1)

    For primers 14–25 nucleotides in length:

    $${T}_m=\left[{2}^{{}^{\circ}}C\times \left(\mathrm{number}\ \mathrm{of}\ \mathrm{A}\ \mathrm{and}\ \mathrm{T}\ \mathrm{bases}\right)\right]+\left[{4}^{{}^{\circ}}C\times \left(\mathrm{number}\ \mathrm{of}\ \mathrm{G}\ \mathrm{and}\ \mathrm{C}\ \mathrm{bases}\right)\right]$$
Fig. 1
figure 1

Schematic representation of AS-PCR

Statistical analysis

Statistical analysis was performed by using SPSS software (V. 20.0). Chi-square test or Fisher’s test whichever appropriate for homogeneity of proportions was used to determine significance of mutation pattern and odds ratio was used to determine association of presence of mutations with various clinico-epidemiological characteristics such as age, site of tumor, clinical tumor stage, and histo-pathological grade of tumor. Statistical significance was considered when p < 0.05.

Fig. 2
figure 2

Representative picture of ARMS-PCR products for detection of 15 bp deletion in exon 19 of EGFR gene. A single tube reaction in which “M” contains molecular marker (100 bp); L1, L2, L3, and L4 contain 444 bp and 325 bp bands representing absence of deletion; L6 contains 444 bp and 134 bp bands representing the presence of 15 bp deletion; L4 and L6 contain 444 bp, 325 bp, and 134 bp bands representing the heterozygosity; L7 represents negative control

Fig. 3
figure 3

Representative picture of AS-PCR products for detection of T790M mutation in exon 20 of EGFR gene. Two tube reaction in which lanes marked as “W” contain bands pertaining to wild allele and “V” contains bands pertaining to variant allele of same sample. “M” contains molecular marker (100 bp); “W1” contains 139 bp band pertaining to wild type allele, “V1” contains 146 bp band pertaining to mutant/variant allele; “NC” represents negative control

Fig. 4
figure 4

Representative picture of AS-PCR products for detection of L858R mutation in exon 21 of EGFR gene. Two tube reaction in which lanes marked as “W” contain bands pertaining to wild allele and “V” contains bands pertaining to variant allele of same sample. “M” contains molecular marker (100 bp); “W1” contains 137 bp band pertaining to wild type allele, “V1” contains 134 bp band pertaining to mutant/variant allele; “NC” represents negative control

Table 1 Primers, product size and annealing temperatures used to detect mutations, if any, in various exons of EGFR gene by ARMS-PCR and AS-PCR


As shown in Table 2 most of our patients were females 44 (73%). Forty-five (75%) of our population were in age group of < 45 years. Most of our patients were non-smokers 50 (83.3%). Neck swelling was the commonest presentation 55(91.6%). PTC 48(80%) was the commonest type of thyroid cancer. Lymph node metastasis was present in 32(53.4%) of patients.

Table 2 Demographic and clinico-pathological variables in our study population

EGFR 15 bp deletion (exon 19) was present in 32(53.3%) of patients, out of which 22 (68.75%) were females. There was more frequent involvement of this mutation in patients with high TSH level (> 5.5 IU/ml) which was statistically significant (p < 0.001). There was preponderance of PTC (29 vs 3) in patients bearing these mutations which was significant (p = 0.04) (Table 3).

Table 3 Association of EGFR 15 bp deletion in exon 19 with different variables of thyroid cancer patients

EGFR T790M (exon 20) was found in 5 (8.4%) patients. It was exclusively present in those tumors in which there was vascular/capsular invasion and it was statistically significant (p = 0.01) (Table 4).

Table 4 Association of EGFR T790M mutation in exon 20 with different variables of thyroid cancer patients

Prevalence of EGFR L858R mutation in our study population was 43.3% (26). 54.3% (19) married individuals were positive for this mutation and it was significant (p = 0.04). Twelve (63.25%) patients with poorly differentiated thyroid cancer bore this mutation and was statistically significant (p = 0.03) (Table 5).

Table 5 Association of EGFR L858R mutation in exon 21 with different variables of thyroid cancer patients


Previous studies have failed to identify EGFR activating mutation in thyroid cancer [9, 19] in contradiction to our study. Possible reason could be that our study was focused on a specific population, i.e., Asian patients who were mostly non-smokers. As for NSCLC (non-small cell lung carcinoma) the EGFR-activating mutations are observed in a particular subset of patients; specifically, mutations are more common in never-smokers, women, Asians, and patients with adenocarcinoma. Lack of smoking history, the most common carcinogen of NSCLC, implies the possibility that other genetic and environmental factors contribute to the development of EGFR mutations.

Our study constituted predominantly females (73%) as compared to males (27%) is almost consistent with previous study [20] in which females are 2.9 times higher. Female preponderance could be due to polymorphism role of estrogen receptor [9, 19, 21]. There is a significant cell proliferation in thyroid cancer tissue in females due to estrogen [21]. PTC was the commonest histologic type in our study population, which is consistent with other study [22].

High TSH (> 5.5 IU/ml) was predominately found in patients with EGFR 15 bp deletion and it was significant. Although there are no such studies in literature that have found such relationship, but hypothyroid status has been found to be linked to thyroid malignancy [23, 24].

The overall 15 bp deletion rate in EGFR exon 19 among 60 patients was found to be 53.3% (32/60). Out of them, 60.5% (29/48) deletions were detected in PTC and only 25.0% (03/12) in FTC. Exon 19 mutational study was also done in relation to lung cancers and it was found that the EGFR exon 19 insertions are a newly appreciated family of EGFR-TKI–sensitizing mutations, and patients with tumors harboring these mutations should be treated with EGFR-TKI. While these mutations may be missed through the use of some mutation-specific assays, the addition of PCR product size analysis to multi-gene assays allows sensitive detection of both exon 19 insertion and deletion mutations [25]. Nevertheless, detailed studies were not done in case of thyroid malignancy. In the future, we can predict the use of tyrosine kinase inhibitors [TKIs] as a treatment modality for advanced/undifferentiated thyroid malignancy in this part of world.

Many studies showed the presence of T790M gene mutations with EGFR domain of exon 20, these studies were conducted in lung carcinoma and the effect of targeted based TKIs was studied in detail [26, 27]. The total mutational rate of T790M in EGFR tyrosine kinase domain (exon 20) among 60 patients was found to be only 8.4% (05 of 60). Only 8.3% of mutations were detected in PTC (04 of 48) as well as in FTC (01 of 12) patients (P > 0.05). Importance of T790M gene mutations with thyroid malignancy needs a detailed study.

The total of 43.3% (26 of 60) of thyroid cancer patients were positive for L858R mutation in EGFR tyrosine kinase domain of exon-21. Though probably such mutation has not been studied in thyroid cancer, there are studies in which similar type has been studied in lung cancer [28, 29]. There was preponderance of L858R mutation in our married cohort, which was statistically significant. SEER study [30] which was conducted between 2002 and 2007 to find out effect of marital status and various other factors on the prognosis of cancer. It showed married people had better cancer specific survival than unmarried (p < 0.05) ones. The presence of these mutations in married individuals with thyroid cancer needs elaborative study.


In our study, we extensively studied the role of EGFR mutations with thyroid cancers, and various mutations in exon 19, 20, and 21.Significant relations of multiple variables were seen in associations with above described EGFR domain. This study will provide a nidus for future scope of further elaborating the clinical aspect of EGFR in the management of differentiated as well as aggressively behaving anaplastic thyroid malignancy in our part of world and at the same time will encourage many to take this study further in assuming a vital background for more elaborate work on thyroid malignancy.

Availability of data and materials

It is not publicly available but is available with the corresponding author.



Epidermal growth factor receptor


Papillary thyroid carcinoma


Poorly differentiated carcinoma


Well-differentiated carcinoma


Follicular thyroid carcinoma


Tyrosine kinase inhibitor


Non-small cell lung carcinoma


Polymerase chain reaction


Allele specific polymerase chain reaction


Medullary thyroid carcinoma


Mitogen activated protein kinase


Thyroid-stimulating hormone


Phosphoinositide 3-kinase


Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results


Amplification refractory mutation system


Anaplastic thyroid cancer


Phosphate-buffered saline


Lymph node metastasis


Extrathyroidal extension


  1. Horner M, Ries L, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER Cancer Statistics Review, 1975-2006. Vol. 23. Bethesda: National Cancer Institute; 2009. p. 143–56.

    Google Scholar 

  2. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–7.

    Article  Google Scholar 

  3. Schlumberger M, Baudin E, Travagli JP. Papillary and follicular cancers of the thyroid. Presse Medicale Paris Fr 1983. 1998;27(29):1479–81.

    CAS  Google Scholar 

  4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.

    Article  Google Scholar 

  5. Morris LGT, Myssiorek D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg. 2010;200(4):454–61.

    Article  Google Scholar 

  6. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol R Coll Radiol G B. 2010;22(6):395–404.

    Article  CAS  Google Scholar 

  7. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda: National Cancer Institute; 2011. Based on November 2010 SEER Data Submission, Posted to the SEER Web Site

    Google Scholar 

  8. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3- CA, and AKT1. Cancer Res. 2009;69(11):4885–93.

    Article  CAS  Google Scholar 

  9. Lee DH, Lee GK, Kong S, Kook MC, Yang SK, Park SY, et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol. 2007;60(8):881–4.

    Article  Google Scholar 

  10. Hoffmann S, Burchert A, Wunderlich A, Wang Y, Lingelbach S, Hofbauer LC, et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine. 2007;31(2):105–13.

    Article  CAS  Google Scholar 

  11. Hoffmann S, Maschuw K, Hassan I, Wunderlich A, Lingelbach S, Ramaswamy A, et al. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. Endocrine. 2006;30(1):129–38.

    Article  CAS  Google Scholar 

  12. Rodríguez-Antona C, Pallares J, Montero-Conde C, Inglada-Pérez L, Castelblanco E, Landa I, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer. 2010;17(1):7–16.

    Article  Google Scholar 

  13. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106–16.

    Article  CAS  Google Scholar 

  14. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39(1):15–20.

    Article  CAS  Google Scholar 

  15. Masago K, Asato R, Fujita S, Hirano S, Tamura Y, Kanda T, et al. Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer. 2009;124(11):2744–9.

    Article  CAS  Google Scholar 

  16. Knauf JA. Does the epidermal growth factor receptor play a role in the progression of thyroid cancer? Thyroid. 2011;21(11); 21:1171–4.

    Article  Google Scholar 

  17. Ricarte-Filho JC, Matsuse M, Lau C, Ryder M, Nishihara E, Ghossein AR, et al. Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. Int J Cancer. 2012;130(9):2215–7.

    Article  CAS  Google Scholar 

  18. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Prev Biomark. 2009;18(4):1092–100.

    Article  Google Scholar 

  19. Maha R, Kallel I, Charfeddine S, Hamza F, Guermazi F, Rebaï A. Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk. J Recept Signal Transduct. 2009;29(2):113–8.

    Article  CAS  Google Scholar 

  20. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Chara-lambous E, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab. 2006;91(9):3662–6.

    Article  CAS  Google Scholar 

  21. Zeng Q, Chen GG, Vlantis AC, van Hasselt CA. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif. 2007;40(6):921–35.

    Article  CAS  Google Scholar 

  22. Rao DN. Epidemiological Observations of Thyroid Cancer. Thyroid cancer- an Indian perspectiveRadiation Medicine Centre, Bhabha Atomic Research Centre and Tata Memorial Hospital; 2000.

    Google Scholar 

  23. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol. 2003;12(2):69–90.

    Article  Google Scholar 

  24. Goellner JR, Gharib H, Grant CS. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 1987;31(5):587–90.

    CAS  PubMed  Google Scholar 

  25. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(1):43–8.

    Article  CAS  Google Scholar 

  26. Bean J, Brennan C, Shih J-Y, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104(52):20932–7.

    Article  CAS  Google Scholar 

  27. Jiang SX, Yamashita K, Yamamoto M, Piao CJ, Umezawa A, Saegusa M, et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer. 2008;123(11):2480–6.

    Article  CAS  Google Scholar 

  28. Rivas C, Martinez LA, Teran EE. Prevalence of epidermal growth factor receptor (EGFR) mutation in an Ecuadorian population with non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15 suppl):e19157.

    Article  Google Scholar 

  29. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.

    Article  CAS  Google Scholar 

  30. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2007;12(1):20–37.

    Article  Google Scholar 

Download references


We are highly grateful to the Department of Pathology SKIMS for giving histopathology diagnosis to our specimens. We fully appreciate the work of Department of Biochemistry SKIMS for their role in mutation analysis.


This study was funded by Institutional intramural grant.

Author information

Authors and Affiliations



Mir, TA did detailed history, took sample, and processed them. Wani, MA did thyroidectomy/lobectomy. Qadir, A analyzed data and prepared the manuscript. Maqsood, MA finally reviewed the manuscript. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Ajaz Qadir.

Ethics declarations

Ethics approval and consent to participate

This study was approved by Institutional Ethical Committee of SKIMS. Proper consent was taken from patients who were willing to participate in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information


Additional file 1.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mir, T.A., Qadir, A., Wani, M.A. et al. Spectrum of EGFR mutation and its relation with high-risk predictors in thyroid cancer in Kashmiri population: 2 years prospective study at a tertiary care hospital. J Egypt Natl Canc Inst 34, 43 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Papillary carcinoma (PC)
  • Follicular carcinoma (FC)
  • Epidermal growth factor receptor (EGFR)